Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Therapeutic potential of regulatory T cells in preeclampsia-opportunities and challenges
Author: Robertson, S.A.
Green, E.S.
Care, A.S.
Moldenhauer, L.M.
Prins, J.R.
Hull, M.L.
Barry, S.C.
Dekker, G.
Citation: Frontiers in Immunology, 2019; 10(MAR):478-1-478-18
Publisher: Frontiers Media
Issue Date: 2019
ISSN: 1664-3224
Statement of
Sarah A. Robertson, Ella S. Green, Alison S. Care, Lachlan M. Moldenhauer, Jelmer R. Prins, M. Louise Hull, Simon C. Barry and Gustaaf Dekker1
Abstract: Inflammation is a central feature and is implicated as a causal factor in preeclampsia and other hypertensive disorders of pregnancy. Inflammatory mediators and leukocytes, which are elevated in peripheral blood and gestational tissues, contribute to the uterine vascular anomalies and compromised placental function that characterize particularly the severe, early onset form of disease. Regulatory T (Treg) cells are central mediators of pregnancy tolerance and direct other immune cells to counteract inflammation and promote robust placentation. Treg cells are commonly perturbed in preeclampsia, and there is evidence Treg cell insufficiency predates onset of symptoms. A causal role is implied by mouse studies showing sufficient numbers of functionally competent Treg cells must be present in the uterus from conception, to support maternal vascular adaptation and prevent later placental inflammatory pathology. Treg cells may therefore provide a tractable target for both preventative strategies and treatment interventions in preeclampsia. Steps to boost Treg cell activity require investigation and could be incorporated into pregnancy planning and preconception care. Pharmacological interventions developed to target Treg cells in autoimmune conditions warrant consideration for evaluation, utilizing rigorous clinical trial methodology, and ensuring safety is paramount. Emerging cell therapy tools involving in vitro Treg cell generation and/or expansion may in time become relevant. The success of preventative and therapeutic approaches will depend on resolving several challenges including developing informative diagnostic tests for Treg cell activity applicable before conception or during early pregnancy, selection of relevant patient subgroups, and identification of appropriate windows of gestation for intervention.
Keywords: Pregnancy; preeclampsia; placenta; embryo implantation; maternal vascular adaptation; inflammation; Treg cells; immune tolerance
Rights: © 2019 Robertson, Green, Care, Moldenhauer, Prins, Hull, Barry and Dekker. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
RMID: 0030112052
DOI: 10.3389/fimmu.2019.00478
Grant ID:
Appears in Collections:Obstetrics and Gynaecology publications

Files in This Item:
File Description SizeFormat 
hdl_119316.pdfPublished Version856.3 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.